Outcomes Of Patients With Solid Tumour Malignancies Treated With First-Line (1l) Immuno-Oncology (Io) Agents Who Do Not Meet Eligibility Criteria For Clinical Trials

ANNALS OF ONCOLOGY（2020）

引用 3|浏览3

暂无评分

摘要

Thirty-two percent of real-world patients treated with contemporary 1L IO-based therapies were ineligible for clinical trials. Although one-third of the trial-ineligible patients responded to treatment, the overall trial-ineligible population had inferior outcomes than trial-eligible patients. These data may guide patient counselling and temper expectations of benefit.

查看译文

关键词

Clinical outcomes,Clinical trial ineligible,IMDC,Immuno-oncology,Immunotherapy,Melanoma,Non–small-cell lung cancer,Real-world patients,Renal cell carcinoma,Trial eligibility

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要